Companies › Novadip Biosciences
2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Other; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NVD003 Autologous 3D osteogenic implant for bone reconstruction | – | Phase 3 | Congenital Pseudarthrosis of Tibia; Recalcitrant Lower Limb Nonunion | Jul 2027 |
| NVDX3 Implantable device for degenerative lumbar spondylolisthesis | – | Phase 1 | Degenerative Lumbar Spondylolisthesis; Distal Radius Fractures | Mar 2036 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05961956 | NVDX3 | Phase 1 | Degenerative Lumbar Spondylolisthesis | Other | Apr 2026 |
| NCT07112443 | NVD003 | Phase 3 | Congenital Pseudarthrosis of Tibia | Other | Jul 2027 |
| NCT06335394 | NVD003 | Phase 1 | Recalcitrant Lower Limb Nonunion | Other | May 2028 |
| NCT06532253 | NVDX3 | Phase 1 | Distal Radius Fractures | Other | Mar 2036 |
No annotated target.
–
Harmony Biosciences Management Tortugas Neuroscience Atsena Therapeutics Shanghai Ark Biopharmaceutical Heron Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.